The Committee for Medicinal Products for Human Use recommends marketing approval for Merck's Keytruda for treating two types ...

The phase III KEYFORM-007 study, evaluating Merck's Keytruda plus favezelimab for treating metastatic colorectal cancer, ...

The Japanese MHLW has granted approval for MSD’s KEYTRUDA (pembrolizumab) for lung and urothelial cancer indications.

An attempt by Merck & Co. to unlock the microsatellite stable (MSS) metastatic colorectal cancer market has ended in failure.

Merck follows in the footsteps of Bristol Myers Squibb, which in December 2023 also failed to secure a late-stage victory for ...

Merck's Phase 3 KEYFORM-007 study on the combination of favezelimab and pembrolizumab in MSS mCRC patients did not improve ...

The FDA has approved Merck's Keytruda (pembrolizumab) in combination with pemetrexed and platinum chemotherapy for first-line ...

Merck (MRK) stock is in focus as a Phase 3 trial for its cancer drug Keytruda in colorectal cancer patients did not meet ...

Recent headlines about a potent new immunotherapy have mostly focused on the U.S. company helping to develop it. Less ...

Summit Therapeutics’ ivonescimab has the potential to challenge Merck’s blockbuster checkpoint inhibitor in non-small cell ...

The EMA CHMP has recommended approval of MSD’s KEYTRUDA for two gynaecological cancers: endometrial and cervical.

Among patients with high-risk muscle-invasive urothelial carcinoma, postsurgical Keytruda extended the time some lived ...